CA
NZ
UK
AU
IND
US
With this capital injection, Jasper aims to advance its promising pipeline of therapies focused on immune-mediated diseases that present significant patient needs. This financial backing is a important step for Jasper, paving the way for key development milestones in the upcoming quarters.
Lantern Pharma Inc. (NASDAQ: LTRN) announced a significant decrease in its second quarter loss from operations, which fell approximately 25% year over year to around $3.5 million. This positive trend reflects the company's ongoing focus on operational discipline and strategic management, demonstrating its capability …
Cue Biopharma, Inc. (NASDAQ: CUE) achieved $7.9 million in revenue for the second quarter ended June 30, 2026, marking a substantial rise from $3.0 million in the same period of the previous year. This revenue growth was attributed to revenue recognized from a milestone …
Dyadic International Inc. (NASDAQ: DYAI) has entered into a registered direct offering that will see an aggregate of 3,625,000 shares of its common stock sold at a price of $0.795 per share. This mechanism bypasses a traditional public offering, allowing the company to receive …
The revenue stream from LYMPHIR® highlights the strong momentum generated since its market debut, signaling that the product is resonating with oncology providers who are actively seeking novel therapeutic options. This uplift is directly linked to an expanding pipeline of cumulative orders, which has …
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) achieved revenue of $7.1 million from the sales of its immunotherapy product LYMPHIR during the first nine months of fiscal 2026. The financial results, released on August 14, reflect a continuing positive trajectory for the biopharmaceutical company's flagship product, …
Climb Bio, Inc. (NASDAQ: CLYM) has begun dosing its first patient in a Phase 2 clinical trial that focuses on immunoglobulin A nephropathy. This marks a key moment for the company's efforts in advancing treatmentOptionsfor patients affected by this condition. The collaboration with Beijing …
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has officially suspended all orders and shipments of its biocosmeceutical products, including the ExoCR and BioX lines, effective August 7, 2026. This suspension is part of a strategic review aimed at evaluating the regulatory compliance and documentation associated with …
Cerenome, Inc. posted a net loss of $9 million, or $1.31 per share, for the second quarter ending June 30, 2026. This figure contrasts sharply with a net income of $5.2 million during the same quarter in 2025. The shift in financial performance is …
BeyondSpring Inc. (NASDAQ: BYSI) reported a net loss of $1.8 million for the second quarter ending June 30, 2026, slightly improved from a $1.9 million loss in the same quarter a year prior. The company’s financial updates coincide with a strategic leadership transition aimed …
Please wait processing your request...